Alexander Guminski MD Of The University of Sydney Discusses Phase 2 Study Of Cemiplimab: Response Rate Of 49 Estimated PFS Is 18.5 Months, Estimated Median OS At 2 Years Is 70.
Phase 2 Study Of Cemiplimab: Response Rate Of 49 Estimated PFS Is 18.5 Months, Estimated Median OS At 2 Years Is 70
By Editor